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Summary
BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-
lineage acute lymphoblastic leukaemia that occurs within cases without
recurrent molecular rearrangements. Gene expression profiling (GEP) can
identify these cases but it is expensive and not widely available. Using GEP,
we identified 10 genes specifically overexpressed by BCR/ABL1-like ALL
cases and used their expression values – assessed by quantitative real time-
polymerase chain reaction (Q-RT-PCR) in 26 BCR/ABL1-like and 26 non-
BCR/ABL1-like cases to build a statistical “BCR/ABL1-like predictor”, for
the identification of BCR/ABL1-like cases. By screening 142 B-lineage ALL
patients with the “BCR/ABL1-like predictor”, we identified 28/142 BCR/
ABL1-like patients (197%). Overall, BCR/ABL1-like cases were enriched in
JAK/STAT mutations (P < 0001), IKZF1 deletions (P < 0001) and rear-
rangements involving cytokine receptors and tyrosine kinases (P = 0001),
thus corroborating the validity of the prediction. Clinically, the BCR/ABL1-
like cases identified by the BCR/ABL1-like predictor achieved a lower rate
of complete remission (P = 0014) and a worse event-free survival
(P = 00009) compared to non-BCR/ABL1-like ALL. Consistently, primary
cells from BCR/ABL1-like cases responded in vitro to ponatinib. We pro-
pose a simple tool based on Q-RT-PCR and a statistical model that is cap-
able of easily, quickly and reliably identifying BCR/ABL1-like ALL cases at
diagnosis.
Keywords: Acute lymphoblastic leukaemia, BCR/ABL1-like, adults,
prognosis, tyrosine kinase inhibitors.
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Among B-lineage acute lymphoblastic leukaemia (ALL),
BCR/ABL1-like ALL is one of the most clinically relevant
subsets because it is characterized by a poor outcome and
could potentially benefit from the use of tyrosine kinase inhi-
bitor (TKI) therapy (Ofran & Izraeli, 2017). Mullighan et al
(2009a) identified a subgroup of paediatric B-lineage ALL
(B-ALL) with a gene expression profile similar to that of
BCR/ABL1-positive patients, frequent IKZF1 deletions and
poor outcome. Simultaneously, Den Boer et al (2009) per-
formed gene expression profiling (GEP) analysis on a cohort
of paediatric B-ALL cases and termed this subgroup BCR/
ABL1-like; it represented 15–20% of B-ALL cases, showed an
unfavourable outcome and was associated with IKZF1, TCF3,
EBF1, PAX5 and VPREB1 deletions, and upregulation of
CRLF2.
Subsequently, the BCR/ABL1-like ALL subgroup has been
extensively evaluated, particularly in paediatric cohorts
(Mullighan et al, 2009b,c; Harvey et al, 2010a,b; Yoda et al,
2010; Chen et al, 2012; Asai et al, 2013; van der Veer et al,
2013) and more recently in adults (Tokunaga et al, 2013;
Boer et al, 2015a; Herold et al, 2017; Jain et al, 2017a;
Roberts et al, 2017). In addition to the association with
IKZF1 deletions and CRLF2 deregulation, Roberts et al
(2012) unveiled that kinase activating alterations character-
ize the majority (91%) of paediatric BCR/ABL1-like ALL
cases. The most frequent alterations involve ABL1, JAK2,
PDGFRB, CRLF2 and EPOR, activating mutations of IL7R,
FLT3-internal tandem duplication mutations and deletion
of SH2B3 (Roberts et al, 2012, 2014a). Several of these
alterations are targeted by TKIs, suggesting a potential role
for tailored treatment (Roberts et al, 2012, 2014a). Further-
more, all authors confirmed an association with poor out-
come, while the relationship with minimal residual disease
(MRD) is still debated (Roberts et al, 2014b; Heatley et al,
2017).
Despite this in-depth genetic characterization, the identifi-
cation of BCR/ABL1-like patients is still challenging: it relies
on GEP and/or a multistep approach, such as a combination
of next generation sequencing (NGS) and fluorescence in situ
hybridisation (FISH) (Roberts et al, 2014a). However, GEP is
largely cohort/experiment-dependent and a consensus diag-
nostic signature has not been agreed upon (Boer et al,
2015b). Similarly, NGS is costly and requires bioinformatic
skills. Alternatively, these cases can be recognized with Low
Density Assay (LDA) of selected genes, but the full method-
ology has not been published (Harvey et al, 2013). Thus, this
study aimed to: (i) produce an easy, rapid and reproducible
assay, based on quantitative real time-polymerase chain
reaction (Q-RT-PCR) analysis, for the recognition of BCR/
ABL1-like ALL cases; (ii) define the molecular background,
clinico-biological features and outcome of the cases thus
identified; and (iii) verify the in vitro response of primary
BCR/ABL1-like ALL cells to the pan-TKI, ponatinib. The
final goal is to provide a rapid, user-friendly and economi-
cally-viable diagnostic tool that can recognize these cases at
presentation, a step towards a refined prognostic and thera-
peutic management of these poor prognosis patients.
Methods
Identification of BCR/ABL1-like cases and genes
To identify the core BCR/ABL1-like cases and BCR/ABL1-
like specific genes (Figure S1), we used two in house GEP
cohorts: GEP1, run on HG-U133 plus2 (Affymetrix, Santa
Clara, CA, USA) – comprising 148 B-ALL cases (70 BCR/
ABL1-positive and 78 B-NEG, i.e. negative for BCR/ABL1,
ETV6/RUNX1, TCF3/PBX1 and KMT2A rearrangements)
(Haferlach et al, 2010; Messina et al, 2010) – and GEP2 –
including 79 cases (37 BCR/ABL1-positive and 42 B-NEG)
(Chiaretti et al, 2005) – evaluated with an older version
of the array (HG-U95 Av2, Affymetrix). In both GEP1
and GEP2, a t-test between BCR/ABL1-positive and
B-NEG cases was performed to recognize the BCR/ABL1-
like ALL cases. B-NEG cases clustering within the BCR/
ABL1-positive cluster were regarded as the “core” BCR/
ABL1-like samples.
To select the BCR/ABL1-like genes (Figure S2), the 16
“core” BCR/ABL1-like ALL cases of GEP1 were compared
with the remaining 62 B-NEG cases by t-test. The genes
selected by this approach were compared with the literature
(Harvey et al, 2010b) and the overlapping genes, together
with CRLF2 (Yoda et al, 2010; van der Veer et al, 2013;
Chiaretti et al, 2016; Herold et al, 2017), were used to build
the Q-RT-PCR-based BCR/ABL1-like predictor. GEP analyses
are detailed in Data S1.
Development and validation of the “BCR/ABL1-like
predictor”
To generate the BCR/ABL1-like predictor, we validated the
expression levels of the selected genes in the discovery
cohort, including 26 core BCR/ABL1-like samples (16 from
GEP1 and 10 from GEP2) and 26 non-BCR/ABL1-like
selected from GEP1. The quantification of transcript levels
was performed by Q-RT-PCR (Data S1 and Table SI) and
computed as 2DCt.
Q-RT-PCR results were used to build the “BCR/ABL1-like
predictor”, extensively described in the Data S1. Briefly,
expression values were shrunk into principal components
(PCs) and a logistic regression model was used to examine
the association among the PCs and BCR/ABL1-like ALL
cases. Subsequently, a score on PCs was built and used to
classify 142 additional B-NEG ALL cases, representing the
screening panel.
The analysis of the genetic and clinical features was per-
formed on a total of 194 B-NEG ALL, 52 belonging to the
discovery and 142 to the screening panels (Table SII and
Data S1). Patients were enrolled in Gruppo Italiano Malattie
EMatologiche dell’Adulto (GIMEMA) and Associazione
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Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) pro-
tocols (Table SIII).
The study was approved by the local IRB, in accordance
with the Helsinki Declaration.
Analysis of genetic features
Recurrently mutated JAK/STAT and RAS pathways genes
(Messina et al, 2016) were sequenced in 182/194 samples
(Table SIV). Copy number aberrations (Messina et al, 2017)
were assessed by multiplex ligation-dependent probe amplifi-
cation (MLPA) in 111/194 samples. RNA-sequencing was
performed in 54 samples by the TruSeq RNA Sample Prepa-
ration Kit (Illumina, San Diego, CA). RNA libraries were
paired-end sequenced (2 9 100 bp) using the Illumina
HiSeq2500 platform. Identification of fusion transcripts was
performed by STAR-fusion (STAR-Fusion_v0.5.1) and
Fusioncatcher (v0.99.3e) (Nicorici et al, 2014).
Statistical analysis of clinical features and event-free
survival (EFS)
Patients’ characteristics were compared by chi-squared or
Fisher’s exact test for categorical variables and by Wilcoxon
test for continuous data. Event-free survival (EFS) and over-
all survival (OS) was estimated by Kaplan–Meier: EFS was
estimated from the time of diagnosis to the occurrence of
refractoriness, relapse or death, while OS was estimated from
the time of diagnosis to death. Multivariate analysis was per-
formed using the Cox proportional model to adjust the effect
of BCR/ABL1-like ALL cases to white blood cell (WBC)
count, age and CRLF2 on EFS. All tests were two-sided and
P values <005 were considered statistically significant. Analy-
ses were performed using the SAS software (release 9.4; SAS
Institute, Cary, NC, USA).
In vitro experiments
To assess the sensitivity to ponatinib, the annexin V/7-ami-
noactinomycin D (7AAD) apoptotic test (BD Bioscience, San
Jose, CA) and 3H-thymidine (Perkin Elmer, Waltham, MA)
proliferation assays were performed on primary cells from 7
BCR/ABL1-like, 6 non-BCR/ABL1-like and 4 BCR/ABL1-posi-
tive cases. Ponatinib (Selleck Chemicals, Houston, TX) at
0 lmol/l (dimethyl sulfoxide only) or at increasing doses
(001–10 lmol/l) was added at time 0 and viability was mea-
sured after 48 and 72 h (Data S1).
Results
Identification and quantification of BCR/ABL1-like
predictor genes in the discovery cohort
The comparison of BCR/ABL1-positive and B-NEG cases of
GEP1 (Haferlach et al, 2010; Messina et al, 2010) using a
t-test recognized 16 B-NEG cases that clustered with the
BCR/ABL1-positive cases: these 16 misclustered B-NEG cases
were regarded as the “core” BCR/ABL1-like samples
(Figure S2).
To select the BCR/ABL1-like genes (Figure S2) the “core”
BCR/ABL1-like ALL cases were compared with the remaining
B-NEG cases by t-test, that resulted in the identification of
285 genes (Table SV), of which 9 had been previously
reported as part of the BCR/ABL1-like signature (Harvey
et al, 2010b). These 9 genes (SOCS2, IFITM1, CD99,
TP53INP1, IFITM2, JCHAIN, NUDT4, ADGRE5 and
SEMA6A) together with CRLF2 (Yoda et al, 2010; van der
Veer et al, 2013; Herold et al, 2017) were used to build the
Q-RT-PCR-based BCR/ABL1-like predictor.
By analysing GEP2 (Chiaretti et al, 2005) we selected 10
additional BCR/ABL1-like ALLs, leading to a total of 26
BCR/ABL1-like cases that were included in the discovery
panel of this study.
Next, the expression levels of these 10 genes were quan-
tified by Q-RT-PCR in the discovery cohort (n = 52), com-
prising 26 BCR/ABL1-like and 26 non-BCR/ABL1-like ALLs,
classified according to GEP (Chiaretti et al, 2005; Haferlach
et al, 2010; Messina et al, 2010). All genes were signifi-
cantly overexpressed in BCR/ABL1-like ALL samples
(Figure S3).
Development of the “BCR/ABL1-like predictor”
The Q-RT-PCR expression values of the 10 genes were used
to build the “BCR/ABL1-like ALL predictor”. First, we veri-
fied that in univariate analysis, all genes were risk factors for
a higher BCR/ABL1-like ALL probability (Table SVI). As a
high correlation was detected among the expression levels of
the 10 genes (Figure S4), it was possible to summarize the
variability by means of PC analysis; by definition, the PCs
thus identified are uncorrelated. In detail, expression values
were shrunk into 3 PCs (accounting for >80% of the vari-
ability): the contributions of each gene to each component
are expressed by factor loadings, a measure of their relation-
ship (Table SVII). Each component is mainly explained by
genes with the highest loadings: PC1 is explained by the
expression values of NUDT4, SEMA6A, ADGRE5, SOCS2 and
JCHAIN, PC2 by CRLF2, TP53INP1, CD99 and PC3 by
IFITM1 and IFITM2.
Second, a logistic regression model was used to estimate
the probability of a case being BCR/ABL1-like using the first
3 PCs; all components were statistically significant in multi-
variate analysis (Table SVIII).
Finally, to generate a predictive model, a score was com-
puted by means of a linear combination of the PCs, as a
result of the above mentioned multivariate logistic regression
model. Figure S5 illustrates the generation of the score. The
optimal cut-off was set at 030: cases with a score ≥030
were defined as BCR/ABL1-like. This cut-off provides the
best distinction between BCR/ABL1-like and non-BCR/ABL1-
S. Chiaretti et al
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like cases and ensures the optimal compromise between sen-
sitivity and specificity (885% and 100%, respectively). The
mathematical equation is provided in Data S1.
An online BCR/ABL1-like score calculator was imple-
mented into the web-based application GIMEMA REDCap
system hosted at GIMEMA Foundation (Harris et al, 2009).
Identification of the BCR/ABL1-like ALL cases and
genomic characterization
The predictive model was then validated in a screening
cohort of 142 B-NEG ALL patients: 28 cases (197%) were
classified as BCR/ABL1-like (min score 0279, max score
2176) and 114 as non-BCR/ABL1-like ALL (min score
1810, max score 0353). The comparison of the clinico-
biological features of BCR/ABL1-like and non-BCR/ABL1-like
ALL cases at diagnosis, carried out in the whole cohort,
showed that BCR/ABL1-like ALLs were associated with a sig-
nificantly higher WBC count at diagnosis (229 vs.
126 9 109/L, P = 0013) while no differences were observed
for the other parameters (Table I).
Recurrently mutated genes were investigated in 182/194
cases. Mutations of the JAK/STAT pathway (i.e. JAK1/2,
CRLF2 and IL7R) were detected in 442% (23/52) of BCR/
ABL1-like cases and only in 77% (10/130) of the non-BCR/
ABL1-like cases (P < 0001), RAS pathway mutations were
more frequent in non-BCR/ABL1-like (n = 38/130, 292%)
than in BCR/ABL1-like cases (n = 9/52, 173%, P = 0068).
Details are provided in Table II.
We also examined copy number aberrations in 111 cases:
IKZF1 deletions were significantly more frequent in BCR/
ABL1-like than non-BCR/ABL1-like cases (828% vs. 408%,
P < 0001). We found that EBF1 and BTG1 deletions were
significantly more frequent in BCR/ABL1-like cases
(Table II).
Finally, CRLF2 levels were significantly higher (P ≤ 0001)
in BCR/ABL1-like (median DCt = 67, range 06–166) than
in non-BCR/ABL1-like cases (median DCt = 113, range 32–
179). Complete results are detailed in Tables SIX and SX.
Comparable results were obtained when separating the dis-
covery (Table SXI) and screening cohorts (Table III).
RNA-sequencing, performed in 54 samples (28 BCR/
ABL1-like and 26 non-BCR/ABL1-like), identified 13 fusion
transcripts targeting tyrosine kinases (TKs)/cytokine recep-
tors, of which 12 were detected in BCR/ABL1-like cases (12/
28 vs. 1/26 P = 0001). The most recurrent fusion was EBF1/
PDGFRB found in 3 cases; JAK2 rearrangements with differ-
ent partners (i.e. PAX5, EBF1, SSBP2) were detected in 3
other cases, P2RY8/CRLF2 and TSLP-fusion genes in 2 sam-
ples; finally, RCSD1/ABL1 and TRIM24/FGFR1 were found in
1 case each. Within non-BCR/ABL1-like cases, 1 case har-
boured P2RY8/CRLF2 while no fusion genes targeting TKs
were documented. Figure 1 shows that 27/28 (964%) had at
least one lesion typical of the BCR/ABL1-like profile and sug-
gests that the BCR/ABL1-like profile is sustained by at least 2
different mechanisms: one represented by TK-rearrangements
only and the other by CRLF2 overexpression plus JAK/STAT
mutations.
Outcome of the BCR/ABL1-like ALL samples
We analysed the complete remission (CR) rate and survival
in the adolescents and adults with clinical data available
(n = 142, Table SIII).
In the whole cohort, the CR rate was lower in BCR/ABL1-
like than in non-BCR/ABL1-like cases (778% vs. 896%,
P = 006).
Consistently, EFS at 36 months was significantly inferior
for BCR/ABL1-like cases compared to non-BCR/ABL1-like
cases (216% vs. 472%, P < 00001; Fig 2A).
When we considered the screening cohort only (n = 95),
we confirmed that the CR rate was significantly lower in
BCR/ABL1-like than in non-BCR/ABL1-like cases (714%
vs. 918%, P = 0014). Similarly, EFS at 36 months was sig-
nificantly inferior for BCR/ABL1-like cases compared to
non-BCR/ABL1-like cases (213% vs. 433%, P = 00009;
Fig 2B).
In line with EFS estimates, OS at 36 months was signifi-
cantly inferior for BCR/ABL1-like cases compared to
non-BCR/ABL1-like cases (373% vs. 607%, P = 005;
Figure S6A) in the whole cohort and a similar trend was
observed in the screening cohort only (Figure S6B). The
Table I. Comparison between BCR/ABL1-like and non-BCR/ABL1-like clinico-biological features.
BCR/ABL1-like n = 54 Non-BCR/ABL1-like n = 140 P-value
Gender (male/female) 36/18 78/62 P = ns
Median age (range), years 32 (6–72) 28 (0–78) P = ns
Age cohort 0–15 years (n = 21) 2 (95%) 19 (905%)
Age cohort 15–35 years (n = 98) 29 (295%) 69 (704%) P = ns
Age cohort >35 years (n = 75) 23 (306%) 52 (693%)
Median (range) WBC count, x109/l 226 (189–239) 124 (06–425) P = 0023
Median (range) platelet count, x109/l 47 (015–283) 47 (1–308) P = ns
Median (range) Hb g/l 97 (41–153) 89 (37–158) P = ns
ns, not significant; WBC, white blood cell.
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impact of BCR/ABL1-like prediction retained statistical sig-
nificance on EFS in multivariate analysis (Hazard ratio:
212, 95% confidence interval: 118–382, P = 001) in a
model adjusted for age and WBC count. We also evaluated
the interaction on EFS between the BCR/ABL1-like
signature and CRLF2 overexpression: BCR/ABL1-like
prediction retained statistical significance on EFS
(P = 005) in the bivariate model adjusted by CRLF2 over-
expression.
In vitro sensitivity to ponatinib
After 72 h of incubation with ponatinib (001 lmol/l), a
3H-thymidine uptake assay showed that the proliferation
Table II. Comparison between BCR/ABL1-like and non-BCR/ABL1-like genetic features.
BCR/ABL1-like Non-BCR/ABL1-like P-value
JAK/STAT pathway members mutated cases 23/52 (442%)* 10/130 (77%) P < 0001
JAK1/2 mutations 14/52 (269%) 4/130 (31%) P < 0001
CRLF2 mutations 6/52 (115%) 2/130 (15%) P = 0007
IL7R mutations 6/52 (115%) 4/130 (31%) P = 0033
RAS pathway members mutated cases 9/52 (173%) 38/130 (292%)† P = 0068
FLT3 mutations 0/52 (0%) 10/130 (77%) P = 0031
KRAS/NRAS mutations 9/52 (173%) 30/130 (231%) P = ns
IKZF1 deletions 29/35 (828%) 31/76 (408%) P < 0001
EBF1 deletions 14/35 (40%) 5/76 (66%) P < 0001
BTG1 deletions 10/35 (286%)# 5/76 (66%) P = 0003
CRLF2 overexpressing cases‡ 33/54 (611%) 25/140 (178%) P < 0001
CRLF2 expression levels 67 (06–166) 109 (32–179) P < 0001
TK/cytokine receptor fusions EBF1/PDGFRB (N = 3) P2RY8/CRLF2 (N = 1)
JAK2-fusions (N = 3)
RCSD1/ABL1 (N = 1)
TRIM24/FGFR1 (N = 1)
P2RY8/CRLF2 (N = 2) 1/26 (38%) P = 0001
TSLP-fusions (N = 2)
12/28 (428%)
*Three cases carried 2 concomitant JAK/STAT pathway mutations: 2 cases harboured JAK2 and CRLF2 mutations, 1 case harboured IL7R and
CRLF2 mutations.
†Two cases carried 2 concomitant RAS pathway mutations: 1 case harboured NRAS and KRAS mutations, 1 case FLT3 and NRAS mutations.
‡Overexpression was defined at DCt < 8 as previously described by Chiaretti et al (2016).
#Correction added on 17 May 2018, after first online publication: The percentage has been corrected from 2064% to 286%.
Table III. Comparison between BCR/ABL1-like and non-BCR/ABL1-like ALL cases included in the screening panel.
BCR/ABL1-like Non-BCR/ABL1-like P-value
JAK/STAT pathway members mutated cases 12/27 (444%)* 10/107 (93%) P < 0001
JAK1/2 mutations 7/27 (259%) 4/107 (37%) P = 0001
CRLF2 mutations 2/27 (74%) 2/107 (19%) ns
IL7R mutations 4/27 (148%) 4/107 (37%) P = 005
RAS pathway members mutated cases 6/27 (222%) 32/107 (299%)† ns
FLT3 mutations 0 9/107 (84%) ns
KRAS/NRAS mutations 6/27 (222%) 24/107 (224%) ns
IKZF1 deletions 14/18 (777%) 23/62 (371%) P = 0029
EBF1 deletions 6/18 (333%) 4/62 (65%) P = 0007
BTG1 deletions 4/18 (222%) 4/62 (65%) P = 0071
CRLF2 overexpressing cases 16/28 (571%) 21/114 (184%) P < 0001
CRLF2 median expression levels (range) 76 (2–166) 113 (32–175) P < 0001
TK/cytokine receptor fusions JAK2-fusions (N = 1) P2RY8/CRLF2 (N = 1) P = 0037
TRIM24/FGFR1 (N = 1) 1/21 (47%)
TSLP-fusions (N = 2)
4/13 (307%)
ns, not significant.
*One case harboured IL7R and CRLF2 mutations.
†One 1 case harboured NRAS and FLT3 mutations.
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rate of primary cells from 7 BCR/ABL1-like cases (2 EBF1/
PDGFRB-positive, 1 JAK2-mutated and P2RY8/CRLF2-posi-
tive, 1 RCSD1/ABL1, 3 WT for JAK/STAT and RAS muta-
tions) decreased to 336%  15%, comparable to the
sensitivity observed in 4 BCR-ABL1-positive cases (443-
%  124%). Contrarily, in the non-BCR-ABL1-like (non-
BCR-ABL1-positive) samples (n = 6) – all WT for JAK/
STAT and RAS hotspot mutations – the proliferation rate
upon ponatinib treatment decreased only to 715-
%  287% (P = 00007) (Fig 3A). Ponatinib (001 lmol/l)
also increased the apoptotic rate in both BCR/ABL1-
like and BCR/ABL1-positive primary ALL cells
(221%  10%, 199%  85%, respectively), while the
apoptotic response in non-BCR/ABL1-like/non-BCR/ABL1-
positive ALL was significantly inferior (61%  84%,
P = 0023, Fig 3B).
Discussion
Although the recognition of the BCR/ABL1-like ALL subset
dates back to 2009, a consensus on a BCR/ABL1-like signa-
ture has not been reached (Den Boer et al, 2009; Mullighan
et al, 2009a) and a standardized tool to identify these cases is
currently not available (Ofran & Izraeli, 2017). Roberts et al
(2014a) and Fasan et al (2015) proposed a combination of
different methods: analysis of CRLF2 expression, FISH target-
ing ABL1 and JAK activating rearrangements, fusion-specific
RT-PCR for the identification of the ABL and JAK partners
Figure 1. Distribution of BCR/ABL1-like specific genetic lesions in the samples with a complete molecular characterization. Legend: green boxes
for JAK/STAT pathway mutations: wild-type; red boxes: mutation detected. The mutated gene name is provided in the figure; green boxes for
RAS pathway mutations: wild-type; red boxes: mutation detected; the mutated gene name is provided in the figure; CRLF2 expression; red boxes:
overexpression; TK/cytokine fusions: green boxes: no rearrangement detected; red boxes: rearrangement detected. The fusion gene is specified in
the figure; IKZF1 deletions: green boxes: no deletions; blue boxes: presence of deletions; grey boxes: sample not evaluated.
Figure 2. Event-free survival at 36 months of adolescents and adults classified as BCR/ABL1-like and non-BCR/ABL1-like belonging to the whole
cohort (A) and the screening panel only (B).
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and MRD monitoring. However, this approach relies on
multiple techniques and can only recognise cases carrying
already known fusion transcripts.
Simultaneously, Harvey et al (2013) developed a method
based on the quantification of 15 transcripts by LDA and
several groups adopted this method (Heatley et al, 2017;
Reshmi et al, 2017). However, the mathematical equations
were not provided. Our approach took advantage of previ-
ously reported GEP data (Chiaretti et al, 2005; Messina et al,
2010) to identify a narrow list of 10 transcripts (CRLF2,
SOCS2, IFITM1, CD99, TP53INP1, IFITM2, JCHAIN,
NUDT4, ADGRE5, SEMA6A), capable of accurately identify-
ing the BCR/ABL1-like ALLs.
The genes chosen to build the predictive model are also in
common with other algorithms recently used to identify
BCR/ABL1-like cases (Roberts et al, 2012; Harvey et al,
2013).
Using Q-RT-PCR of these 10 transcripts, we built an algo-
rithm capable of identifying BCR/ABL1-like cases with a high
sensitivity and specificity. Furthermore, we generated a user-
friendly tool, which requires only the upload of gene expres-
sion values to assess whether a sample is BCR/ABL1-like or
non-BCR/ABL1-like.
Next, the screening of 142 B-NEG ALL samples by the
BCR/ABL1-like predictor assigned 28 cases (197%) to the
BCR/ABL1-like ALL subset, in line with the reported inci-
dence (Ofran & Izraeli, 2017).
The prediction accuracy was indirectly corroborated by
the analysis of the genetic features of BCR/ABL1-like ALL
cases. As reported in both paediatric and adult cohorts, BCR/
ABL1-like ALL is associated with IKZF1 deletions, CRLF2
deregulation/rearrangements, JAK1/2 mutations, rearrange-
ments of genes coding for TKs and cytokine receptors (Mul-
lighan et al, 2009b,c; Harvey et al, 2010a,b; Yoda et al, 2010;
Chen et al, 2012; Asai et al, 2013; Tokunaga et al, 2013; van
der Veer et al, 2013; Boer et al, 2015a; Ge et al, 2016; Herold
et al, 2017; Jain et al, 2017a; Roberts et al, 2017). Consis-
tently, our BCR/ABL1-like cases frequently carried JAK/STAT
pathway mutations, the most recurrent targeting JAK2, fol-
lowed by CRLF2 and IL7R. In addition, BCR/ABL1-like cases
were enriched in IKZF1 deletions, detected in 80% of cases,
in line with Herold and colleagues (Herold et al, 2017).
More importantly, RNA-sequencing – performed in 28
BCR/ABL1-like cases - revealed that 7 carried TK rearrange-
ments, 2 P2RY8/CRLF2 and 2 TSLP-rearrangements. TK-acti-
vating fusion genes are specific to BCR/ABL1-like cases and
may be targeted by TKIs, as shown in pre-clinical models
and sporadic case reports (Maude et al, 2012; Roberts et al,
2012, 2014a,c; Tasian et al, 2012; Lengline et al, 2013; Wes-
ton et al, 2013; Shi et al, 2014, 2015; Francis et al, 2016).
The integration of all the molecular features, feasible in 28
BCR/ABL1-like, demonstrated that 964% had at least one
lesion typical of the BCR/ABL1-like profile and suggested
that the BCR/ABL1-like profile is sustained by at least two
mechanisms, either a TK-activating fusion or CRLF2 overex-
pression with a concomitant JAK/STAT mutation; at vari-
ance, CRLF2 overexpression alone seems insufficient to
induce a BCR/ABL1-like profile.
From a clinical standpoint, the features of the BCR-ABL1-
like cases hereby identified were in line with a BCR-ABL1-
like profile: they displayed a significantly higher WBC count
at diagnosis, a lower CR rate and a significantly worse EFS
than non-BCR-ABL1-like patients; we observed no differences
related to gender, in agreement with other reports (Boer
et al, 2015b; Herold et al, 2017). An association with MRD
levels was not feasible since this parameter was not available
for a large set of patients. Furthermore, the incidence in pae-
diatric cases was lower than in adolescents and adults (95%
vs. 295% and 306%, respectively) in our cohort.
Finally, in vitro experiments showed that the pan-TKI,
ponatinib, the most potent inhibitor in BCR/ABL1-positive
ALL (Jabbour et al, 2015), was able to reduce the prolifera-
tive rate in BCR-ABL1-like samples and to increase apoptosis,
similarly to that observed in BCR-ABL1-positive ALL. Nota-
bly, the BCR-ABL1-like samples analysed by in vitro experi-
ments comprised ABL class lesions, JAK/STAT mutated and
WT cases, indicating that ponatinib is active in all cases
regardless of the underlying lesion and may represent an
alternative to ruxolitinib whose clinical activity remains to be
determined (Jain et al, 2017b).
Figure 3. In vitro response to ponatinib in BCR/ABL1-like and non-
BCR/ABL1-like primary cells; BCR/ABL1+ cells were used as control.
(A) Average values of 3H-thymidine incorporation of 16 primary
B-ALL cells samples after 72 h of treatment with ponatinib
(001 lmol/l); (B) Average values of Annexin V positive primary
B-ALL cells samples after 72 h of treatment with ponatinib
(001 lmol/l). Samples are grouped according to BCR/ABL1-like
(n = 7), BCR/ABL1-positive (n = 4) and non-BCR/ABL1-like
(n = 6).
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In conclusion, we hereby describe a Q-RT-PCR based assay
capable of singling out BCR-ABL1-like patients from the B-
NEG ALL cohort. This approach has many advantages: first, it
requires minimal amounts of diagnostic RNA; second, it is sim-
ple and cost-effective, being based on Q-RT-PCR; third, it is
rapid, because the screening can be completed within a few
days. This is essential, considering the high rate of refractory
cases that – if promptly recognized – could benefit from an
alternative approach, contemplating the use of the pan-TKI,
ponatinib. These advantages make this tool suitable to be intro-
duced in the diagnostic workflow and appears applicable to
many haematology centres, followed by further genomic screens
that comprise RNA-sequencing characterization to fully eluci-
date the underlying molecular lesion in the patients thus identi-
fied. Finally, because this assay is not based on a specific target
identification, it allows the potential recognition of all BCR/
ABL1-like cases, including those carrying novel genetic lesions.
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